The development of new targeted therapies and immunotherapy for lung cancer increased overall survival (OS). In the near future, it is expected an increasing prevalence of long-term lung cancer survivors (LTLCS). Aim: to evaluate the prevalence of LTLCS and describe their characteristics and evolution during follow up. Cross-sectional study that included patients diagnosed with primary lung cancer between Jan/2012 and Dec/2016, with OS greater than 5 years (LTLCS). Patients? demographics, their clinical characteristics and their follow up were analyzed. Lung cancer was diagnosed in 767 patients, 158(20.6%) LTLCS. The percentage of LTLCS increased every year. Most patients were male, median age at diagnosis was 65[56;71] years old, 62.7% had ECOG 0 and 71.5% had current or past smoking habits. The most frequent histology was adenocarcinoma, 66.2% were diagnosed at early stages and did only one treatment, being surgery the first line of treatment in most patients (61.7%). During follow up, 28.7% patients had disease progression or relapse, 77.1% of smokers were no longer smoking and 15.2% developed other tumors. The median number of emergency visits was 3 and hospitalizations 1. From all LTLCS, 40 (25.3%) were dead at the time of the study, only 37.5% from progression of lung cancer disease. Median OS of LTLCS was not reached at 5 years and median OS of death patients was 77 months. LTLCS prevalence increased in recent years. Despite that, about a quarter of patients had disease progression/relapse and 15% patients developed other tumors, reinforcing the importance of follow up and modifying risk factors. In fact, lung cancer diagnosis can be an opportunity to increase smoking cessation.